← All trials
NCT02623556
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Dec 1, 2015
- Primary completion
- Jun 1, 2017
- Completion date
- Jun 1, 2017
- First posted
- —
- Last posted
- —
- Enrollment
- 1080
- Arms / groups
- 2 / —
- Source
- AACT · pre-existing
Sponsors
- Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.Lead sponsor
- Capital Medical UniversityOverall official - principal investigator
- Wuxi NO.5 People's HospitalOverall official - principal investigator
- Tianjin UniversityOverall official - principal investigator
- Chongqing Medical UniversityOverall official - principal investigator
- Fujian Medical UniversityOverall official - principal investigator
- Fudan UniversityCollaborator
- Capital Medical UniversityCollaborator
- Proswell Medical CorporationCollaborator
- Wuxi Hospital for Infectious DiseasesCollaborator
- Chongqing Medical UniversityCollaborator
- Tianjin UniversityCollaborator
- Fujian Medical UniversityCollaborator
- People's Liberation Army of ChinaCollaborator
- Fudan UniversityOverall official - principal investigator
- Huazhong University of Science and TechnologyCollaborator
- Huazhong University of Science and TechnologyOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.